BusinessWeek profiles Margaret McGlynn (photo), president of Merck Vaccines for the past 14 months. During that time, Merck has launched four vaccines, including Gardasil as a protection against cervical cancer. These vaccines are at the center of Merck's plans to revive the company from its post-Vioxx debacle. Gardasil alone is expected to generate $2 billion to $4 billion in annual revenue.
- here's the BusinessWeek report on McGlynn
Merck's Gardasil OK'd for pricey rollout. Report
Idera inks $455M pact for Merck vaccines. Report